Citizens JMP raised the firm’s price target on Ideaya Biosciences (IDYA) to $45 from $41 and keeps an Outperform rating on the shares. Ideaya’s partner Hengrui showed best-in-class efficacy as well as duration compared to the competitive landscape with DLL-3 ADC IDE849 in updated Phase 1 data in Chinese patients, clearing a hurdle with more room than anticipated, the analyst tells investors in a research note. The firm is “very impressed” by the results.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Ideaya Biosciences Advances in Metastatic Uveal Melanoma Treatment Study
- Ideaya, Hengrui Pharma presented initial data from Phase 1 IDE849 trial
- Ideaya Biosciences enrolls first patient in IDE397 trial
- Ideaya Biosciences initiated with an Outperform at Citizens JMP
- Ideaya Biosciences initiated with an Overweight at Barclays